Business
SonoThera Launches $125M Series B at 44th J.P. Morgan Healthcare Conference to Advance Multiple Genetic Medicine Programs Toward First-in-Human Studies
SOUTH SAN FRANCISCO, Calif., January 08, 2026--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will officially launch a $125M Series B funding round at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA January 12-15.
About this update from Jp Morgan Chase & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/14af6f12e915041c404f5766029e5d52"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sSIu_e7ZiD1l1HOReHMlyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/14af6f12e915041c404f5766029e5d52","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/jhbnreIsz7VfGNoLOFce6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/14af6f12e915041c404f5766029e5d52","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"SonoThera is entering a clinical execution phase, advancing multiple genetic medicine programs toward first-in-human studies.","length":125,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Lead clinical programs include Duchenne muscular dystrophy (DMD), autosomal dominant polycystic kidney disease (ADPKD), and X-linked Alport syndrome (XLAS).","length":156,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The Company’s proprietary RIPPLE™ ultrasound-mediated delivery technology enables nonviral, highly targeted biodistribution of diverse genetic payloads without size restriction.","length":177,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":458,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., January 08, 2026--(BUSINESS WIRE)--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will officially launch a $125M Series B funding round at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA January 12-15.","length":383,"tagName":"p"},{"type":"text","content":"Since 2022, SonoThera has developed and established its proprietary RIPPLE™ technology and optimized it across multiple non-human primate (NHP) target organs. These efforts have generated compelling preclinical data demonstrating the ability of Ultrasound Mediated Delivery (UMD) to enable broad, highly targeted biodistribution of diverse genetic payloads—without size restriction—and in a manner that ...